Key Points
- Director Magda Marquet sold 11,000 shares on January 15 at an average price of $48.23 for $530,530, leaving her with 9,930 shares and representing a 52.56% reduction in her ownership.
- AnaptysBio reported a strong quarter—$76.32M revenue vs. $15.83M consensus and EPS of $0.52 vs. (-$1.06) expected—and its board authorized a $100 million stock repurchase plan to buy up to roughly 9.6% of outstanding shares.
- Shares recently opened at $45.68 (52‑week range: $12.21–$52.47), the company has a market cap of about $1.26 billion, and analysts' consensus is a "Moderate Buy" with an average price target of $60.40.
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director Magda Marquet sold 11,000 shares of AnaptysBio stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $48.23, for a total transaction of $530,530.00. Following the completion of the transaction, the director directly owned 9,930 shares in the company, valued at $478,923.90. This trade represents a 52.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
AnaptysBio Price Performance
Shares of ANAB opened at $45.68 on Friday. The firm has a 50 day simple moving average of $43.71 and a two-hundred day simple moving average of $32.32. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $52.47. The company has a market cap of $1.26 billion, a P/E ratio of -16.20 and a beta of 0.32.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The firm had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. On average, analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.
AnaptysBio announced that its board has authorized a stock repurchase plan on Friday, November 21st that allows the company to repurchase $100.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to purchase up to 9.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's leadership believes its stock is undervalued.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the stock. Wall Street Zen raised shares of AnaptysBio from a "buy" rating to a "strong-buy" rating in a report on Sunday, November 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of AnaptysBio in a research report on Wednesday, October 8th. UBS Group assumed coverage on shares of AnaptysBio in a research report on Wednesday, January 7th. They issued a "buy" rating and a $70.00 target price on the stock. Wells Fargo & Company upped their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the stock an "overweight" rating in a report on Wednesday, November 5th. Finally, Stifel Nicolaus dropped their price target on AnaptysBio from $80.00 to $56.00 and set a "buy" rating for the company in a research note on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $60.40.
Check Out Our Latest Report on AnaptysBio
Hedge Funds Weigh In On AnaptysBio
Several institutional investors and hedge funds have recently added to or reduced their stakes in ANAB. HighMark Wealth Management LLC raised its position in shares of AnaptysBio by 58.2% during the second quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company's stock worth $3,231,000 after acquiring an additional 53,550 shares during the last quarter. Panagora Asset Management Inc. bought a new stake in AnaptysBio in the second quarter valued at approximately $741,000. Allianz Asset Management GmbH acquired a new stake in AnaptysBio during the 2nd quarter valued at approximately $337,000. Los Angeles Capital Management LLC bought a new position in AnaptysBio during the 2nd quarter worth approximately $334,000. Finally, 683 Capital Management LLC lifted its position in shares of AnaptysBio by 155.6% in the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company's stock worth $11,100,000 after purchasing an additional 304,373 shares during the period.
AnaptysBio Company Profile
(
Get Free Report)
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
